• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

眼动脉化疗治疗 ICRb D 和 E 眼视网膜母细胞瘤后的视网膜电图与视力结局的关系。

Association of electroretinography with visual outcomes after ophthalmic artery chemosurgery for retinoblastoma in ICRb D and E eyes.

机构信息

Memorial Sloan Kettering Cancer Center, Ophthalmic Oncology Service, New York, United States of America.

University of Utah, Moran Eye Center, Salt Lake City, United States of America.

出版信息

PLoS One. 2019 Jan 16;14(1):e0210647. doi: 10.1371/journal.pone.0210647. eCollection 2019.

DOI:10.1371/journal.pone.0210647
PMID:30650131
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6334963/
Abstract

IMPORTANCE

Predictions of visual outcomes are useful in clinical and family decisions regarding treatment for retinoblastoma. Very little has been published on the association of post-treatment visual acuity with pre-treatment electroretinography (ERG), which can be performed on infants too young to reliably quantify visual acuity.

OBJECTIVE

To report associations of pre-treatment ERG with post-treatment visual acuity in eyes with advanced retinoblastoma treated with ophthalmic artery chemosurgery (OAC).

DESIGN

Retrospective case-control study of eyes treated from 2006 through 2017, with mean follow-up of 51 months (range 2.3-150 months).

SETTING

Single large academic center.

PARTICIPANTS

Group D and E eyes treated with OAC at Memorial Sloan Kettering Cancer Center with recorded visual acuity and ERG (30Hz flicker).

MAIN OUTCOME AND MEASURE

Snellen visual acuity (uncorrected) compared to initial 30Hz flicker ERG.

RESULTS

This study included 157 Group D and E eyes. Results of the Jonckheere-Terpstra test for trend were statistically significant and indicated that eyes with lower pre-treatment ERG readings tended to have more visual impairment post-treatment. Among eyes with initial ERG 75+ μV, 11 of 32 eyes (34%) had visual acuity 20/40 or better. Among eyes with ERG 0 μV, 44 of 46 (96%) had visual acuity of 20/200 or worse.

CONCLUSIONS AND RELEVANCE

Eyes with advanced intraocular retinoblastoma treated with OAC can achieve excellent visual acuity, but poor ERG at initial visit is associated with poor visual acuity after treatment in the majority of eyes. Expectations regarding visual potential may influence decisions about treatment.

摘要

重要性

对于视网膜母细胞瘤的治疗,预测视力结果对于临床和家庭决策非常有用。很少有关于治疗前视网膜电图(ERG)与治疗后视力之间的关联的报道,而 ERG 可以在太小而无法可靠地量化视力的婴儿身上进行。

目的

报告接受眼动脉化疗(OAC)治疗的晚期视网膜母细胞瘤眼的治疗前 ERG 与治疗后视力之间的关系。

设计

对 2006 年至 2017 年接受治疗的眼进行回顾性病例对照研究,平均随访 51 个月(范围 2.3-150 个月)。

地点

单一大专科学院。

参与者

在纪念斯隆凯特琳癌症中心接受 OAC 治疗并记录视力和 ERG(30Hz 闪烁)的 D 组和 E 组眼。

主要结果和措施

与初始 30Hz 闪烁 ERG 相比的 Snellen 视力(未矫正)。

结果

这项研究包括 157 只 D 组和 E 组眼。Jonckheere-Terpstra 趋势检验结果具有统计学意义,表明治疗前 ERG 读数较低的眼在治疗后往往视力更差。在初始 ERG 为 75+μV 的眼中,32 只眼中有 11 只(34%)视力为 20/40 或更好。在 ERG 为 0μV 的眼中,46 只眼中有 44 只(96%)视力为 20/200 或更差。

结论和相关性

接受 OAC 治疗的眼内晚期视网膜母细胞瘤可以获得极佳的视力,但在大多数眼中,初次就诊时的 ERG 较差与治疗后视力较差相关。对视觉潜力的期望可能会影响治疗决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a8/6334963/573e958a3ba8/pone.0210647.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a8/6334963/3979da41fe34/pone.0210647.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a8/6334963/573e958a3ba8/pone.0210647.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a8/6334963/3979da41fe34/pone.0210647.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a8/6334963/573e958a3ba8/pone.0210647.g002.jpg

相似文献

1
Association of electroretinography with visual outcomes after ophthalmic artery chemosurgery for retinoblastoma in ICRb D and E eyes.眼动脉化疗治疗 ICRb D 和 E 眼视网膜母细胞瘤后的视网膜电图与视力结局的关系。
PLoS One. 2019 Jan 16;14(1):e0210647. doi: 10.1371/journal.pone.0210647. eCollection 2019.
2
Simultaneous Bilateral Ophthalmic Artery Chemosurgery for Bilateral Retinoblastoma (Tandem Therapy).双侧视网膜母细胞瘤同步双侧眼动脉化学手术(串联疗法)
PLoS One. 2016 Jun 3;11(6):e0156806. doi: 10.1371/journal.pone.0156806. eCollection 2016.
3
Ophthalmic artery chemosurgery for eyes with advanced retinoblastoma.晚期视网膜母细胞瘤眼部的眼动脉化学手术
Ophthalmic Genet. 2017 Jan-Feb;38(1):16-21. doi: 10.1080/13816810.2016.1244695. Epub 2017 Jan 17.
4
Efficacy and toxicity of second-course ophthalmic artery chemosurgery for retinoblastoma.视网膜母细胞瘤第二次眼动脉化学手术的疗效与毒性
Ophthalmology. 2015 May;122(5):1016-22. doi: 10.1016/j.ophtha.2014.11.029. Epub 2015 Jan 21.
5
Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review.眼动脉化疗治疗低度眼内视网膜母细胞瘤:5 年回顾。
PLoS One. 2012;7(4):e34120. doi: 10.1371/journal.pone.0034120. Epub 2012 Apr 24.
6
Efficacy and Toxicity of Intravitreous Chemotherapy for Retinoblastoma: Four-Year Experience.玻璃体内化疗治疗视网膜母细胞瘤的疗效与毒性:四年经验
Ophthalmology. 2017 Apr;124(4):488-495. doi: 10.1016/j.ophtha.2016.12.015. Epub 2017 Jan 12.
7
Retinal reattachment and ERG recovery after ophthalmic artery chemosurgery for advanced retinoblastoma in eyes with minimal baseline retinal function.在基线视网膜功能极低的眼中,对晚期视网膜母细胞瘤进行眼动脉化学手术后的视网膜复位及视网膜电图恢复情况
Br J Ophthalmol. 2017 May;101(5):623-628. doi: 10.1136/bjophthalmol-2016-308591. Epub 2016 Aug 18.
8
Current Treatment of Bilateral Retinoblastoma: The Impact of Intraarterial and Intravitreous Chemotherapy.当前双侧视网膜母细胞瘤的治疗:动脉内和玻璃体内化疗的影响。
Neoplasia. 2018 Aug;20(8):757-763. doi: 10.1016/j.neo.2018.05.007. Epub 2018 Jun 22.
9
Total retinal detachments due to retinoblastoma: Outcomes following intra-arterial chemotherapy/ophthalmic artery chemosurgery.因视网膜母细胞瘤导致的全视网膜脱离:眼动脉化疗/眼动脉化学外科治疗后的结局。
PLoS One. 2018 Apr 26;13(4):e0195395. doi: 10.1371/journal.pone.0195395. eCollection 2018.
10
Electroretinogram monitoring of dose-dependent toxicity after ophthalmic artery chemosurgery in retinoblastoma eyes: six year review.视网膜母细胞瘤眼行眼动脉化疗术后剂量依赖性毒性的视网膜电图监测:六年回顾
PLoS One. 2014 Jan 20;9(1):e84247. doi: 10.1371/journal.pone.0084247. eCollection 2014.

引用本文的文献

1
Ocular survival after intra-arterial chemotherapy for retinoblastoma improves with accrual of experience and programmatic evolution.眼内动脉化疗治疗视网膜母细胞瘤的眼存活率随着经验的积累和项目的发展而提高。
Pediatr Blood Cancer. 2023 Feb;70(2):e30071. doi: 10.1002/pbc.30071. Epub 2022 Nov 8.
2
Retinoblastoma management in 13q deletion syndrome patients using super-selective chemotherapies and other cancer-directed interventions.13q 缺失综合征患者采用超选择性化疗和其他癌症靶向干预治疗视网膜母细胞瘤。
Pediatr Blood Cancer. 2021 May;68(5):e28845. doi: 10.1002/pbc.28845. Epub 2020 Dec 23.
3
Clinical spectrum and treatment outcome of retinoblastoma with Group D and E diseases: A single institution retrospective review.

本文引用的文献

1
Current Treatment of Bilateral Retinoblastoma: The Impact of Intraarterial and Intravitreous Chemotherapy.当前双侧视网膜母细胞瘤的治疗:动脉内和玻璃体内化疗的影响。
Neoplasia. 2018 Aug;20(8):757-763. doi: 10.1016/j.neo.2018.05.007. Epub 2018 Jun 22.
2
Ten-year experience with ophthalmic artery chemosurgery: Ocular and recurrence-free survival.眼动脉化疗 10 年经验:眼部和无复发生存。
PLoS One. 2018 May 23;13(5):e0197081. doi: 10.1371/journal.pone.0197081. eCollection 2018.
3
Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis.
D组和E组视网膜母细胞瘤的临床谱及治疗结果:单机构回顾性研究
Medicine (Baltimore). 2020 Sep 18;99(38):e22201. doi: 10.1097/MD.0000000000022201.
4
Intra-arterial chemotherapy in retinoblastoma - A paradigm change.眼内动脉化疗治疗视网膜母细胞瘤——一种范式转变。
Indian J Ophthalmol. 2019 Jun;67(6):740-754. doi: 10.4103/ijo.IJO_866_19.
静脉化疗与眼内动脉化疗治疗视网膜母细胞瘤的比较:一项荟萃分析。
BMC Cancer. 2018 Apr 27;18(1):486. doi: 10.1186/s12885-018-4406-6.
4
Outcomes of Proton Beam Radiation Therapy for Retinoblastoma With Vitreous Seeds.玻璃体种植性视网膜母细胞瘤的质子束放射治疗结果
J Pediatr Hematol Oncol. 2018 Nov;40(8):569-573. doi: 10.1097/MPH.0000000000001176.
5
Intravitreal topotecan in the management of refractory and recurrent vitreous seeds in retinoblastoma.眼内注射拓扑替康治疗视网膜母细胞瘤难治性和复发性玻璃体内播散。
Br J Ophthalmol. 2018 Apr;102(4):490-495. doi: 10.1136/bjophthalmol-2017-310641. Epub 2017 Aug 26.
6
Long-term Visual Acuity, Strabismus, and Nystagmus Outcomes Following Multimodality Treatment in Group D Retinoblastoma Eyes.D 组视网膜母细胞瘤眼多模态治疗后的长期视力、斜视和眼球震颤结果
Am J Ophthalmol. 2017 Jul;179:137-144. doi: 10.1016/j.ajo.2017.05.003. Epub 2017 May 10.
7
Factors predictive of long-term visual outcomes of Group D eyes treated with chemoreduction and low-dose IMRT salvage: the Children's Hospital Los Angeles experience.D 组眼经化学减瘤和低剂量 IMRT 挽救治疗后长期视力结局的预测因素:洛杉矶儿童医院的经验。
Br J Ophthalmol. 2014 Aug;98(8):1061-5. doi: 10.1136/bjophthalmol-2013-304411. Epub 2014 Mar 26.
8
Visual outcomes following intraophthalmic artery melphalan for patients with refractory retinoblastoma and age appropriate vision.眼内动脉注射氨甲蝶呤治疗难治性视网膜母细胞瘤和符合年龄的视力患者的视力结果。
Br J Ophthalmol. 2013 Nov;97(11):1464-70. doi: 10.1136/bjophthalmol-2013-303694. Epub 2013 Sep 13.
9
Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage.化疗降低风险联合低剂量调强放疗挽救治疗后双眼视网膜母细胞瘤 D 组眼的长期疗效
Pediatr Blood Cancer. 2013 Apr;60(4):688-93. doi: 10.1002/pbc.24303. Epub 2012 Sep 19.
10
ERG monitoring of retinal function during systemic chemotherapy for retinoblastoma.全身化疗治疗视网膜母细胞瘤过程中的视网膜功能 ERG 监测。
Br J Ophthalmol. 2012 Jun;96(6):877-80. doi: 10.1136/bjophthalmol-2011-301248. Epub 2012 Mar 18.